Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Cost effectiveness of treatment in osteoporosis
Publication date :
1996
Journal title :
Journal of Rheumatology
ISSN :
0315-162X
eISSN :
1499-2752
Publisher :
Journal of Rheumatology Publishing Company, Toronto, Canada
Detsky AS, Naglie IG: A clinician's guide to cost-effectiveness analysis. Ann Intern Med /990/113:147-54.
Drummond MF, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. Toronto: Oxford Medical, 1987:1-182.
Parker MJ, Myles JW, Anand JK, Drewett R: Cost-benefit analysis of hip fracture treatment. J Bone Joint Surg /992;74B:261-.
Chrischilles EA, Shireman T, Wallace RB: Costs and health effects of osteoporotic fractures. Bone 1994; 15:377-86.
Whittington R, Faulds D: Hormone replacement therapy. II. A pharmacoeconomic appraisal of its role in the prevention of postmenpausal osteoporosis and ischaemic heart disease. Pharmacoeconomics 1994;5:513-54.
Clark AP, Schuttinga JA: Targeted estrogen/progestogen replacement therapy for osteoporosis calculation of health care cost savings. Osteoporosis Int 1992:2:195-200.
Watts NB, Harris ST, Genant HK, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Eng/ J Med /990;323:73-9.
Harris ST, Watts NB, Jackson RD, et al: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med /99j,-95:557-67.